Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2635945 | 0.90 | SMN1; SMN2 (0.49) | RAB9ANPC1KMT2AMEN1CYP1A2 | |
| SCHEMBL31495198 | 0.89 | KMT2A (0.52) | RAB9ANPC1KMT2AMEN1CYP1A2 | |
| SCHEMBL16236229 | 0.87 | RAB9A (0.53) | RAB9ANPC1KMT2AMEN1CYP1A2 | |
| SCHEMBL178430 | 0.83 | TAS1R3 (0.66) | RAB9ANPC1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL15341542 | 0.82 | NPC1 (0.54) | RAB9ANPC1KMT2AMEN1CYP1A2 | |
| SCHEMBL1518477 | 0.82 | KMT2A (0.57) | RAB9ANPC1KMT2AMEN1CYP1A2 | |
| SCHEMBL6121489 | 0.82 | HSD17B10 (0.64) | KMT2AMEN1POLB | |
| SCHEMBL4516890 | 0.81 | HPGD (0.68) | RAB9ANPC1KMT2AMEN1TAS1R3 | |
| SCHEMBL20627701 | 0.81 | POLB (0.41) | RAB9ANPC1KMT2AMEN1CYP1A2 | |
| SCHEMBL3233932 | 0.81 | NPC1 (0.53) | RAB9ANPC1CYP1A2CYP2C19TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287077-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2024-08-29 | — | — | US | disclosed |
| CN-111377925-B | Purine derivatives, preparation method thereof and application thereof in medicines | 四川科伦博泰生物医药股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2022-06-30 | — | — | US | disclosed |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2021-01-14 | — | — | US | disclosed |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2021-01-14 | — | — | US | disclosed |
| CN-111377925-A | Purine derivative, preparation method and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| EP-2948439-B1 | PYRAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-03 | — | — | EP | disclosed |
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-6380256-B1 | FOR THERAPY OF DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6369261-B1 | CYCLOPROPYLBENZENE DERIVATIVE OF ACIDS OR ESTERS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| US-6369225-B1 | ENZYME INHIBITORS | ALLERGAN SALES, INC. | 2002-04-09 | — | — | US | disclosed |
| WO-2002026727-A2 | METHODS OF PROVIDING AND USING COMPOUNDS (RETINOIDS) HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359135-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6313107-B1 | ADMINISTERING TO MAMMAL TO TREAT DISEASES RESPONSIVE TO TREATMENT BY RETINOIDS | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-6303785-B1 | SUBSTITUTED N-CYCLOPROPYLTETRAHYDROISOQUINOLINES | ALLERGAN SALES, INC. | 2001-10-16 | — | — | US | disclosed |
| US-6291677-B1 | FOR TREATING SKIN-RELATED DISEASES, INCLUDING, ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-INFLAMMATORY ACNE, PSORIASIS, ICHTHYOSES AND KERATINIZATION AND HYPERPROLIFERATIVE DISORDERS OF SKIN | ALLERGAN SALES, INC. | 2001-09-18 | — | — | US | disclosed |
| US-6252090-B1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN SALES, INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204511-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | RAB9A 1782/4885NPC1 856/4885KMT2A 2243/4885 |
| US-20240287077-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | RAB9A 1782/4885NPC1 856/4885KMT2A 2243/4885 |
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | RAB9A 1263/4885NPC1 487/4885KMT2A 2905/4885 |
| US-20210009595-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | DPYD, CYP3A5, CYP3A7 | RAB9A 1915/4885NPC1 705/4885KMT2A 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.